Interferon-Gamma Release Assays (IGRAs) Market Size is USD 561.32 Million in 2026

The global Interferon-Gamma Release Assays (IGRAs) market is expected to grow significantly, with its size surpassing USD 518.3 million in 2025 and reaching approximately USD 1,150.44 million by 2035. This growth is driven by a robust CAGR of 8.30%, highlighting the rising demand for advanced diagnostic technologies.

Interferon-Gamma Release Assays (IGRAs) Market Statical Scope

Market Overview

What are the Interferon-Gamma Release Assays (IGRAs)?
The interferon-gamma release assays (IGRAs) market is expanding due to the increasing preference for blood-based tests over traditional skin tests for tuberculosis (TB) detection. IGRAs offer advantages such as higher accuracy, no need for follow-up visits, and the ability to distinguish between latent and active TB infections. The market growth is supported by the rising global burden of tuberculosis, particularly in high-risk populations.
Additionally, ongoing advancements in testing technologies and increasing awareness of the benefits of IGRAs are further driving their adoption in healthcare settings.

Interferon-Gamma Release Assays (IGRAs) Market, By Region

• Asia-Pacific: Dominates the market due to high TB prevalence and large-scale screening programs in countries like India and China.
• Europe: Steady adoption driven by government-funded TB control programs and preference for accurate, rapid diagnostics in healthcare settings.
• North America: Significant market presence due to advanced healthcare infrastructure, higher awareness, and adoption in hospitals and clinics.
• Latin America: The IGRA market in Latin America is growing steadily, primarily driven by government and public health initiatives aimed at early detection and control of tuberculosis in high-risk populations.

Segment Insights

Interferon-Gamma Release Assays (IGRAs) Market, By Product Type

• QuantiFERON-TB Gold Plus (QFT-Plus): A widely used blood test that measures the immune response to TB-specific antigens, providing a reliable and accurate diagnosis of latent and active tuberculosis.
• T-SPOT.TB: A blood-based test that detects the immune system's response to TB bacteria by measuring the release of interferon-gamma in response to specific antigens.
• Other IGRA: Includes various lesser-known or emerging interferon-gamma release assays that aim to provide alternative solutions for TB detection, often with specific advantages in certain regions or applications.

Interferon-Gamma Release Assays (IGRAs) Market, By Application

• Latent Tuberculosis Infection (LTBI) Detection: Identifies individuals infected with TB bacteria who do not show symptoms, enabling preventive treatment.
• Active Tuberculosis Diagnosis Support: Assists clinicians in confirming active TB cases when used alongside other diagnostic methods.
• Screening Before Immunosuppressive Therapy: Ensures patients receiving immunosuppressive treatments are tested for TB to prevent reactivation.
• Public Health Surveillance: Supports population-level monitoring and control of TB by detecting infections in high-risk groups.

Interferon-Gamma Release Assays (IGRAs) Market, By End User

• Hospitals and Clinics: Use IGRAs for routine TB screening, diagnosis, and monitoring of patients, especially in high-risk or immunocompromised populations.
• Diagnostic Laboratories: Perform IGRA testing on patient samples to provide accurate TB detection and support clinical decision-making.
• Public Health Departments: Employ IGRAs for large-scale TB surveillance, outbreak control, and preventive screening programs.
• Research Institutions: Utilize IGRAs in studies to develop new TB diagnostics, treatments, and understand TB epidemiology.

Interferon-Gamma Release Assays (IGRAs) Market Share, By Region, 2025 (%)

• North America (40%) — The leading region for IGRA market share, driven by extensive healthcare infrastructure and high tuberculosis awareness and testing.
• Europe (30%) — A mature market with widespread use of IGRAs for tuberculosis diagnosis and monitoring, supported by public health initiatives.
• Asia Pacific (20%) — A growing IGRA market influenced by increasing tuberculosis incidence and expanding healthcare access.
• LAMEA (10%) — A developing IGRA market in regions like Latin America, the Middle East, and Africa, with limited adoption and focus on high-risk populations.

Interferon-Gamma Release Assays (IGRAs) Market Share, By Product type, 2025 (%)

• QuantiFERON-TB Gold Plus (QFT-Plus) (35%) — A widely used IGRA test for diagnosing latent tuberculosis infection (LTBI), leveraging interferon-gamma release to detect Mycobacterium tuberculosis exposure.
• T-SPOT.TB (40%) — An IGRA test that measures T-cell response to Mycobacterium tuberculosis antigens, commonly used in diagnosing both latent and active tuberculosis.
• Other IGRA (25%) — A category covering other interferon-gamma release assays used in various diagnostic and surveillance applications for tuberculosis.

Interferon-Gamma Release Assays (IGRAs) Market Share, By Application, 2025 (%)

• Latent Tuberculosis Infection (LTBI) Detection (30%) — Testing to identify individuals with latent tuberculosis, who are infected but show no active disease symptoms.
• Active Tuberculosis Diagnosis Support (25%) — IGRA applications used in confirming active tuberculosis cases by detecting the immune response to Mycobacterium tuberculosis.
• Screening Before Immunosuppressive Therapy (20%) — IGRA use to screen individuals for tuberculosis infection before they undergo immunosuppressive treatments.
• Public Health Surveillance (25%) — The use of IGRAs in monitoring and controlling tuberculosis outbreaks within populations.